AI assistant
Moderna, Inc. — Director's Dealing 2018
Dec 7, 2018
30610_dirs_2018-12-07_c0a2d0b9-77b6-4e71-b63c-5636a7d31141.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: Moderna, Inc. (MRNA)
CIK: 0001682852
Period of Report: 2018-12-07
Reporting Person: MENDLEIN JOHN (See Remarks)
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 806154 | Direct |
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $10.90 | 2026-02-23 | Common Stock (23853) | Direct | |
| Stock Option (Right to Buy) | $19.15 | 2026-08-10 | Common Stock (9263) | Direct | |
| Stock Option (Right to Buy) | $12.21 | 2027-02-23 | Common Stock (42201) | Direct | |
| Stock Option (Right to Buy) | $14.22 | 2028-02-28 | Common Stock (2981651) | Direct |
Footnotes
F1: This option is fully vested and exercisable.
F2: This option is fully vested and exercisable.
F3: This option is fully vested and exercisable.
F4: 1,834,863 options will vest over 4 years, with 25% vesting on January 2, 2019, and the remaining 75% vesting in equal calendar quarterly installments over the next three years; 688,073 options will vest over 5 years, with 25% vesting on January 2, 2020, and the remaining 75% vesting in equal calendar quarterly installments over the following three years; and 458,715 options will vest over 6 years, with 25% vesting on January 2, 2021, and the remaining 75% vesting in equal calendar quarterly installments over the following three years.